12:00 AM
 | 
May 19, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAP kinase 7 (MAPK7; BMK1; ERK-5); mitogen-activated protein kinase kinase kinase 2 (MAP3K2); WNK lysine deficient protein kinase 1 (WNK1; PPP1R16

Cancer

INDICATION: Prostate cancer

Patient sample, mouse and cell culture studies suggest inhibiting MAPK7 or the MAPK7 pathway components MAP3K2 and WNK1 could help treat prostate adenocarcinoma cancer harboring gain-of-function FOXF1 mutations. In tissue samples from patients with prostate adenocarcinoma, FOXF1...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >